Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05486598
Other study ID # AL8326-CN-009
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 21, 2022
Est. completion date December 2022

Study information

Verified date August 2022
Source Advenchen Laboratories, LLC
Contact Yingyin Li
Phone +8657188683590
Email anne@advenchen.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main study objective: the pharmacokinetic effects of high-fat diet on AL8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects. Secondary study objectives: safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects


Description:

This is a Phase IB Clinical Trial to Evaluate the Effect of High-fat Diet on Pharmacokinetics of AL8326 Tablets in Chinese Healthy Adult Subjects. Sixteen healthy subjects were randomly divided into two sequence groups, a and B, and eight subjects in each sequence group were dosed according to either the fasting → postprandial or the postprandial → fasting sequence. The washout period was 14 days.


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Healthy male or female subjects aged 18 ~ 65 years (including both 18 and 65 years); 2. Body weight = 50 kg for men and = 45 kg for women, with a body mass index in the range 19-26 kg / m^2 (inclusive 19 and 26) (BMI = body weight (kg) / height2 (M2)); 3. No mental abnormalities, no history of cardiovascular, nervous, respiratory, digestive, urinary, endocrine and metabolic abnormalities; 4. Previous history, physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation routine, pregnancy test (female), hepatitis, HIV, syphilis, 12 lead electrocardiogram, chest X-ray and other tests in the screening period, the whole of the results must be within the normal range matched to age and gender, or meet the protocol regulations, or if outside the normal range is judged as "not clinically significant (NCS) "; 5. Those who agree to be abstinent or have taken effective non drug contraception for the duration of the study and for at least 3 months after last study drug administration (for female subjects also required to be abstinent or have taken effective non drug contraception for two weeks prior to study entry); 6. Subject is able to communicate well with investigator and understand and comply with all requirements of this study, understand and sign the informed consent form. Exclusion Criteria: 1. Allergic constitution (allergy to two or more substances) or known allergy to the study drug or to the same drug; 2. The screening period examination was abnormal and clinically significant. 3. Regular use of sedative, hypnotic, or other addictive drugs within 6 months before enrollment; 4. Those with a history of substance abuse or a positive urine drug abuse screen within 12 months prior to enrollment; 5. Those who smoked more than 5 cigarettes per day, or could not stop using any tobacco products during the trial; 6. Regular drinkers with a positive alcohol insufflation test or within 6 months prior to enrollment, who consumed more than 3 units of alcohol per day, or more than 21 units per week (one bottle of 350 ml of beer with 120 ml of liquor or 30 ml of spirits as 1 drinking unit); 7. Use of any prescription drug, Chinese herbal medicine within 4 weeks prior to enrollment, and / or use of any over-the-counter (OTC), food supplement (including vitamins, calcium tablets, etc.) within 2 weeks prior to first dose; 8. Had participated in other clinical trials and taken study drugs within 3 months before enrollment; 9. Having a blood donor (blood donation with ingredients) or blood loss of 400 ml, or having a blood transfusion within 3 months before enrollment; Blood donation (component containing blood donation) or blood loss of 200 ml within 1 month before enrollment (except physiological blood loss in females); 10. History of significant illness or major surgery, trauma, 3 months prior to screening. 11. Had gastrointestinal disease causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome or a history of severe vomiting, diarrhea within the week prior to enrollment; 12. Pregnant, lactating female subjects and reproductive age female subjects unable to provide contraception on request; 13. Hepatitis B surface antigen positive, hepatitis C antibody positive, syphilis antibody positive, HIV antibody positive persons; 14. Special requirements for the diet (including lactose intolerance), inability to comply with the diet provided and respective prescribers; 15. Subject denied discontinuation of any beverage or food containing methylxanthine, e.g., caffeine (coffee, tea, cola, chocolate, etc.), 48 hours prior to first dose until the end of study; 16. Subject denied discontinuation of any beverage or food containing grapefruit 7 days prior to first dose until the end of the study; 17. Intolerance to venipuncture for blood collection or poor vascular status; 18. Subjects who, in the judgment of the investigator, were not suitable for participation in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AL8326 tablets
Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals. Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.

Locations

Country Name City State
China The Affiliated Hospital of Qingdao University Qingdao Shandong

Sponsors (1)

Lead Sponsor Collaborator
Advenchen Laboratories Nanjing Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC0-t Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects. 120 hours after each dose
Primary AUC0-8 Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects. 120 hours after each dose
Primary Cmax Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects. 120 hours after each dose
Secondary Tmax Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects. 120 hours after each dose
Secondary T1/2 Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects. 120 hours after each dose
Secondary Incidence of adverse events / serious adverse events as well as severity Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects. Day 15 (± 1) after the last Administration
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00984009 - A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1